Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TK2 | O00142 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL27538938 | 0.93 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3TK1 | |
| Doxribtimine SCHEMBL860032 | 0.91 | TK1 (0.62) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL325199 | 0.91 | TK1 (0.62) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL29124320 | 0.91 | P2RY2 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3TK1 | |
| Doxribtimine SCHEMBL28320997 | 0.90 | TK1 (0.61) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL27210303 | 0.90 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3TK1 | |
| Uridine SCHEMBL28025505 | 0.89 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| Uridine SCHEMBL9075559 | 0.89 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3TK2 | |
| Uridine SCHEMBL2563446 | 0.89 | SLC28A1 (0.78) | SLC28A1SLC28A2SLC29A1SLC28A3TK1 | |
| Idoxuridine SCHEMBL10383338 | 0.89 | TK1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190003966-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | SENA RESEARCH, INCORPORATED (US) | 2019-01-03 | — | — | US | claimed |
| US-20130183765-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | Sena Research Incorporated (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012037158-A2 | ULTRAVIOLET AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHODS FOR THE EVALUATION OF SUNSCREEN EFFICACY | SENA RESEARCH, INCORPORATED (US) | 2012-03-22 | — | — | WO | claimed |
| CN-117016549-B | Application of nucleoside compound and composition thereof in promoting plant growth | 山东蓬勃生物科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230405003-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-117016549-A | Application of nucleoside compound and composition thereof in promoting plant growth | 山东蓬勃生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4238571-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | OnQuality Pharmaceuticals China Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| CN-116367842-A | Application of thymidine derivative in preparing medicine | 上海岸阔医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20190003966-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | SENA RESEARCH, INCORPORATED (US) | 2019-01-03 | — | — | US | disclosed |
| US-10073033-B2 | Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy | SENA RESEARCH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180119217-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Life Technologies Corporation (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2016153999-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Life Technologies Corporation (US) | 2016-09-29 | — | — | WO | disclosed |
| CN-103232511-B | Light-cleavable group protected deoxyuridine triphosphate derivatives and a synthesis method and applications thereof. | UNIV BEIJING | 2015-06-17 | — | — | CN | disclosed |
| CN-103232511-A | Light-cleavable group protected deoxyuridine triphosphate derivatives and a synthesis method and applications thereof. | UNIV BEIJING | 2013-08-07 | — | — | CN | disclosed |
| US-20130183765-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | Sena Research Incorporated (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037158-A2 | ULTRAVIOLET AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHODS FOR THE EVALUATION OF SUNSCREEN EFFICACY | SENA RESEARCH, INCORPORATED (US) | 2012-03-22 | — | — | WO | disclosed |
| CN-100546589-C | The preparation of caterpillar fungus cephalosporin powder anti-arrhythmia effective part and pharmaceutical preparation thereof | ZHEJIANG MODERN CHINESE MEDICI (CN) | 2009-10-07 | — | — | CN | disclosed |
| CN-1899319-A | Preparation of caterpillar fungus cephalosporin powder anti-arrhythmia effective part and its medicinal preparation | ZHEJIANG MODERN CHINESE MEDICI (CN) | 2007-01-24 | — | — | CN | disclosed |
| CN-1603248-A | Biological denitrification method for ammonium-nitrogen containing waste water and microbes thereof | INST OF SOIL SCIENCE CHINESE A (CN) | 2005-04-06 | — | — | CN | disclosed |
| CN-1076356-C | protein having thrombopoietin activity | KIRIN BREWERY (JP) | 2001-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405003-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | TYMP, DCTD, TYMS | SLC28A1 52/4885SLC28A2 50/4885SLC29A1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.